Over the past decade, the relationships drug developers have with their third-party biomanufacturers has evolved from relatively simple transactional services to integrated and complex strategic partnerships. This podcast replays a panel discussion from EBD's BIO EUROPE Spring event where editor Dan Stanton discusses the changing way pharma works with CDMOs with delegates from Samsung Biologics, Catalent, and AGC Biologics. Topics covered include: The history of CDMOs, M&A within the industry, the advent of new modalities and, of course, the COVID-19 pandemic.